IntelGenx Completes Enrollment for ‘BUENA’ Montelukast VersaFilm® Phase 2a Clinical Trial in Patients with Mild to Moderate Alzheimer’s Disease

Rhea-AI Summary

IntelGenx Corp. has completed patient enrollment in the Montelukast VersaFilm Phase 2a clinical trial for Alzheimer's Disease. The study enrolled 52 patients, 18 fewer than planned, with approval from Health Canada. The company aims to determine the extent of the drug's effect sizes and expects to complete the trial in Q1 2024 and report initial results in Q2 2024. The AD market is projected to reach $13.7 billion in 2030 with a compound annual growth rate of 20%.

Positive

• IntelGenx successfully enrolled 52 patients in the Montelukast VersaFilm Phase 2a clinical trial.
• The study design was modified with approval from Health Canada, allowing for a decrease in study enrollment to avoid further delays.
• The company aims to determine the extent of the drug's effect sizes and optimize the power of the study to detect the effects of Montelukast VersaFilm compared to placebo.
• The trial is expected to be completed in Q1 2024, with initial results reported in Q2 2024.
• The Alzheimer's Disease market is projected to reach $13.7 billion in 2030 with a compound annual growth rate of 20%.

Negative

• None.

Study completion and initial data anticipated in Q1 and Q2 2024, respectively

SAINT LAURENT, Quebec, Aug. 01, 2023 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX:IGX)(OTCQB:IGXT) (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm^® Phase 2a (“BUENA”) clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”).

The Company successfully enrolled 52 patients in the study, 18 fewer than initially planned, in a study design modification that received a No Objection Letter (“NOL”) from Health Canada. The NOL provided authorization to proceed with the study changes. IntelGenx, in consultation with its statistical consultant, Cogstate Ltd., determined that adjusting the p-value (which determines whether a drug effect exists) to p<0.1 will provide a basis for determining the extent to which effect sizes (the size of the drug effect) of 0.6 or greater (0.5 to <0.8 are considered ‘medium’ effect sizes, while 0.8 or greater are considered ‘large’ effect sizes¹) are statistically significant.

“While there have been exciting recent advancements in the treatment of AD, there is no question that significant unmet medical need remains in this large and growing patient population,” said Dwight Gorham, IntelGenx’s CEO. “As the COVID-19 pandemic effectively halted the BUENA trial’s recruitment for approximately 18 months, followed by imposed post-pandemic restrictions from hospitals, our rationale behind decreasing study enrollment was to avoid any further delay in achieving the program’s goal. We are confident that this Health Canada-authorized study design modification will enable us to utilize data from fewer patients while optimizing the power of the study to detect the effects of Montelukast VersaFilm^® compared to placebo. We are looking forward to completing the BUENA trial in the first quarter of 2024 and to reporting initial trial results the following quarter.”

GlobalData recently reported that the AD market is expected to reach $13.7 billion in 2030 across the eight major markets (U.S., France, Germany, Italy, Spain, U.K., Japan, and China), representing a compound annual growth rate of 20.0% from $2.2 billion in 2020. The expansion is primarily attributed to the significant unmet needs posed by AD, combined with the introduction of new therapies, including the recently approved Leqembi and donanemab, which is expected to be approved by year-end.

Reference

¹ Sullivan GM, Feinn R. Using Effect Size-or Why the P Value Is Not Enough. J Grad Med Educ. 2012 Sep;4(3):279-82.

About Montelukast VersaFilm^®

Montelukast is a leukotriene receptor antagonist that was approved by the U.S. Food and Drug Administration in 1997 for the treatment of asthma and seasonal allergic rhinitis. IntelGenx is working to repurpose Montelukast as a therapeutic to treat neurodegenerative diseases by re-formulating the drug into an oral film-based product. IntelGenx's proprietary VersaFilm^® technology is especially suited for special needs patient populations, and the Montelukast VersaFilm^® product offers many distinct advantages over tablets for AD and Parkinson’s Disease patients, including the avoidance and minimization of first-pass-effects, ease of administration, improved API bioavailability, lower dosing and toxicity, better acceptability and improved compliance.

In Phase 1 studies, IntelGenx demonstrated that an oral film formulation of Montelukast is safe and tolerable in healthy subjects, reduces the first-pass-effect and has a 52% higher bioavailability compared to the regular Montelukast tablet, demonstrating a clear advantage of delivering Montelukast via film. IntelGenx's oral film also crossed the blood-brain barrier, an essential feature for treating degenerative brain diseases.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm^®, DisinteQ^™, VetaFilm^® and transdermal VevaDerm^™, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information and Statements

This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(647) 872-4849
stephen@kilmerlucas.com

Or

Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
andre@intelgenx.com

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is IntelGenx Corp.

What is the purpose of the Montelukast VersaFilm Phase 2a clinical trial?

The purpose of the trial is to study the effects of Montelukast VersaFilm in patients with mild to moderate Alzheimer's Disease.

How many patients were enrolled in the study?

A total of 52 patients were enrolled in the study.

What was the reason for the decrease in study enrollment?

The decrease in study enrollment was to avoid further delays in achieving the program's goal.

When is the expected completion of the trial?

The trial is expected to be completed in the first quarter of 2024.

What is the projected size of the Alzheimer's Disease market in 2030?

The AD market is projected to reach $13.7 billion in 2030.